Aurora Cannabis Inc. (ACB)
NASDAQ: ACB · Real-Time Price · USD
4.340
+0.120 (2.84%)
Jan 2, 2026, 4:00 PM EST - Market closed
Aurora Cannabis Revenue
Aurora Cannabis had revenue of 90.37M CAD in the quarter ending September 30, 2025, with 11.40% growth. This brings the company's revenue in the last twelve months to 367.13M, up 23.89% year-over-year. In the fiscal year ending March 31, 2025, Aurora Cannabis had annual revenue of 343.29M with 27.32% growth.
Revenue (ttm)
367.13M CAD
Revenue Growth
+23.89%
P/S Ratio
0.93
Revenue / Employee
342,148 CAD
Employees
1,073
Market Cap
245.35M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 343.29M | 73.66M | 27.32% |
| Mar 31, 2024 | 269.64M | 45.83M | 20.48% |
| Mar 31, 2023 | 223.80M | 2.47M | 1.11% |
| Jun 30, 2022 | 221.34M | -23.91M | -9.75% |
| Jun 30, 2021 | 245.25M | -23.45M | -8.73% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ACB News
- 6 days ago - Trump Is Warming to Cannabis, but Investors Aren't Impressed - WSJ
- 11 days ago - Marijuana Stocks To Watch After The Holidays - MarijuanaStocks
- 16 days ago - Inside the dealmaking that pushed Trump to reclassify pot, expand access - CNBC
- 16 days ago - After Trump's move to reclassify cannabis, here's what Wall Street is thinking - Market Watch
- 16 days ago - Trump just legalized marijuana nationwide — here's why potheads are rejoicing - New York Post
- 17 days ago - Why US banks are still wary of cannabis despite Trump's policy shift - Invezz
- 17 days ago - Cannabis companies face hurdles accessing big banks despite reclassification, experts say - Reuters
- 17 days ago - Donald Trump Has Officially Reclassified Marijuana To A Schedule 3 Substance - MarijuanaStocks